RT Journal Article
SR Electronic
T1 The influence of pH on SARS-CoV-2 infection and COVID-19 severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.10.20179135
DO 10.1101/2020.09.10.20179135
A1 Leandro Jimenez
A1 Ana Campos Codo
A1 Vanderson de Souza Sampaio
A1 Antonio E.R. Oliveira
A1 Lucas Kaoru Kobo Ferreira
A1 Gustavo Gastão Davanzo
A1 Lauar de Brito Monteiro
A1 João Victor Virgilio-da-Silva
A1 Mayla Gabriela Silva Borba
A1 Gabriela Fabiano de Souza
A1 Nathalia Zini
A1 Flora de Andrade Gandolfi
A1 Stéfanie Primon Murano
A1 José Luiz Proença-Modena
A1 Fernando Almeida Val
A1 Gisely Cardoso Melo
A1 Wuelton Marcelo Monteiro
A1 Maurício Lacerda Nogueira
A1 Marcus Vinícius Guimarães Lacerda
A1 Pedro M. Moraes-Vieira
A1 Helder I Nakaya
YR 2020
UL http://medrxiv.org/content/early/2020/09/11/2020.09.10.20179135.abstract
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can infect a broad range of human tissues by using the host receptor angiotensin-converting enzyme 2 (ACE2). Individuals with comorbidities associated with severe COVID-19 display higher levels of ACE2 in the lungs compared to those without comorbidities, and conditions such as cell stress, elevated glucose levels and hypoxia may also increase the expression of ACE2. Here we showed that patients with Barrett’s esophagus (BE) have a higher expression of ACE2 in BE tissues compared to normal squamous esophagus, and that the lower pH associated with BE may drive this increase in expression. Human primary monocytes cultured in reduced pH displayed increased ACE2 expression and viral load upon SARS-CoV-2 infection. We also showed in two independent cohorts of COVID-19 patients that previous use of proton pump inhibitors is associated with 2- to 3-fold higher risk of death compared to those not using the drugs. Our work suggests that pH has a great influence on SARS-CoV-2 Infection and COVID-19 severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Brazilian National Council for Scientific and Technological Development (grant number 313662/2017-7); the Sao Paulo Research Foundation (grant numbers 2018/14933-2; 2018/21934-5; 2017/27131-9; 2013/08216-2; 2020/04836-0); and CAPES.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the Brazilian Committee of Ethics in Human Research (CAAE: 30152620.1.0000.0005 and 30615920.2.0000.0005).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPublicly available transcriptomic data were obtained from the Gene Expression Omnibus (GEO) repository (https://www.ncbi.nlm.nih.gov/geo/)